Rhabdomyosarcoma (RMS) is a highly malignant tumor that is histologically related to skeletal muscle, yet genetic and molecular lesions underlying its genesis and progression remain largely unknown. In this study we have compared the molecular profiles of two different mouse models of RMS, each associated with a defined primary genetic defect known to play a role in rhabdomyosarcomagenesis in man. We report that RMS of heterozygous Patched1 (Ptch1) mice show less aggressive growth and a greater degree of differentiation than RMS of heterozygous p53 mice. By means of cDNA microarray analysis we demonstrate that RMS in Ptch1 mutants predominantly express a number of myogenic markers, including myogenic differentiation 1, myosin heavy chain, actin, troponin and tropomyosin, as well as genes associated with Hedgehog/Patched signaling like insulin-like growth factor 2, forkhead box gene Foxf1 and the growth arrest and DNA-damage-inducible gene Gadd45a. In sharp contrast, RMS in p53 mutants display higher expression levels of cell cycle-associated genes like cyclin B1, cyclindependent kinase 4 and the proliferation marker Ki-67. These results demonstrate that different causative mutations lead to distinct gene expression profiles in RMS, which appear to reflect their different biological characteristics. Our results provide a first step towards a molecular classification of different forms of RMS. If the described differences can be confirmed in human RMS our results will contribute to a new molecular taxonomy of this cancer, which will be critical for gene mutation-and expression-specific therapy.
Introduction
Rhabdomyosarcoma (RMS), the most common softtissue sarcoma in children, falls into the broader category of small blue round cell tumors (Wexler and Helman, 1997) . The currently accepted histological classification scheme differentiates between embryonal (ERMS), botryoid, alveolar (ARMS) and pleomorphic RMS (Horn and Enterline, 1958) . However, RMS exhibit a degree of heterogeneity in their clinical behavior and clinical outcome that cannot be explained by their histology alone (Dagher and Helman, 1999) . The inability to predict the outcome of the disease requires an aggressive treatment regimen that comprises surgery, radiation therapy and chemotherapy (Dagher and Helman, 1999) . The development of a less toxic therapy protocol that decreases long-term morbidity and reduces the risk for secondary neoplasms is therefore of the uttermost importance.
The development of new therapies of RMS has been hampered by a lack of knowledge about the basic molecular mechanisms involved in tumor formation. The difficulty in determining these molecular alterations is in part a result of the low incidence of RMS. Some molecular lesions, such as the chromosomal translocations in ARMS generating PAX3-and PAX7-FKHR fusion proteins (Shapiro et al., 1993; Davis et al., 1994) , or the loss of imprinting (LOI) of insulin-like growth factor 2 (IGF2) in ERMS (Scrable et al., 1987; Zhan et al., 1994) have already been described. However, neither transgenic mice overexpressing Igf2 nor mice expressing Pax3-FKHR develop RMS (Sun et al., 1997; Lagutina et al., 2002) , indicating that these genetic defects may not be the primary events in RMS formation. It is possible that additional genetic changes that do not occur in mice are required, or that the transgenes did not effectively target the appropriate tissue.
In this report we use mouse models to establish the specific molecular signatures of two different forms of RMS, each caused by a defined gene defect, that is, mutation in p53 or PTCH1. Germline mutations in either the transcription factor p53 or the sonic hedgehog receptor PTCH1 lead to cancer syndromes, respectively, Li-Fraumeni (LFS) or Nevoid Basal Cell Carcinoma Syndrome (NBCCS), associated with increased incidence of RMS (Gorlin, 1987; Malkin et al., 1990) . In addition, mutation of p53 and deregulation of the Hedgehog/Patched signaling pathway are detected in a substantial percentage of sporadic RMS (Wexler and Helman, 1997; Ragazzini et al., 2004) . Although both p53 and PTCH1 function as suppressors of tumorigenesis, the signaling pathways in which they are involved are considered to be independent. So far, no study has established an association between the p53 or PTCH1 status with the gene expression profiles and resulting histological subtypes of RMS, although this might have a profound impact on the treatment of this tumor.
Due to the low frequency of either syndrome in humans, we have performed expression profiling on tumors derived from murine models of LFS and NBCCS. Heterozygous p53 þ /À mutant mice develop a number of sarcomas, including RMS (Harvey et al., 1993; Jacks et al., 1994) . RMS are also prevalent in heterozygous Ptch1 neo67/ þ animals (Calzada-Wack et al., 2002) . We show that the RMS encountered in these mice differ in their gene expression patterns and investigate the link between these profiles and their genetic etiology.
Results

Ptch1-and p53-dependent RMS differ extremely in the time of onset and incidence
To exclude possible effects of the different genetic backgrounds on molecular signature of RMS that arise in Ptch1 neo67/ þ and p53 þ /À mice, we first bred the targeted mutations onto a common genetic background by crossing CD-1 Ptch1 neo67/ þ (Hahn et al., 1998 ) with C57BL/6 p53 þ /À mice (Jacks et al., 1994) . The resulting offspring was examined weekly for tumor formation over a period of 550 days. As shown in Figure 1 , heterozygosity for Ptch1 dramatically increases the incidence of tumors arising from skeletal muscle (SMTU ¼ skeletal muscle tumor). Note that not all of the SMTU were histologically confirmed as RMS. Out of 96 animals with the Ptch1 neo67/ þ genotype more than 40% developed grossly visible SMTU within 550 days of age, with a median age of onset of 224 days. Only 20% of p53 þ /À mice developed these tumors in this time, with a median age of onset of 329 days. Double-heterozygous
þ /À mutants developed SMTU with frequencies (37%) and median age of onset (228 days) comparable with the Ptch1 neo67/ þ animals (data not shown). Irrespective of genotype, SMTU most commonly occurred in the trunk and extremities (data not shown). No SMTU were detected in wild-type littermates (data not shown). These results indicate that SMTU originating from heterozygous Ptch1 neo67/ þ and p53 þ /À mice differ dramatically in the time of onset and incidence.
Other tumor types including medulloblastoma (MB), osteosarcoma (OS) and lung adenocarcinoma (LA) were observed in both genotypes. The relative frequency of tumor types in the cohorts is depicted in Figure 2 . The most common tumor types in Ptch1 neo67/ þ mice were SMTU and MB, representing 63 and 27% of total tumors, respectively. In p53 þ /À mice, SMTU, OS, LA and MB were observed in 41, 24, 9 and 4% of total tumors, respectively. Additionally, single cases of lymphoma, leiomyosarcoma, hemangiosarcoma, hepatocellular carcinoma and chondrosarcoma, lipoma and trichoepithelioma were found in p53 þ /À and Ptch1 neo67/ þ animals, respectively.
Ptch1-dependent RMS show a less aggressive growth and are histologically more differentiated than p53-dependent RMS
We performed a comparative immunohistochemical and histological analysis of SMTU of Ptch1 neo67/ þ and p53 þ /À Figure 1 Rhabdomyosarcomagenesis in Ptch1-and p53-mutant mice. 95 p53 þ /À and 96 Ptch1 neo67/ þ mice were monitored for tumors arising from skeletal muscle (SMTU) over a period of 550 days. All mice were from a (CD-1 Â C57BL/6) F1 hybrid background. The cumulative incidence of SMTU, corrected for confounding causes of death, is plotted as a function of age in days. Mice diagnosed with SMTU are represented by open (p53-mutant) and closed squares (Ptch1-mutant), whereas mice that died for other reasons are shown as small vertical bars and Ptch1 neo67/ þ mice. Frequencies were determined from 46 and 63 total tumors in p53 þ /À and Ptch1 neo67/ þ mice, respectively. Animals were monitored for tumors over a period of 550 days Patched-and p53-dependent rhabdomyosarcoma R Kappler et al mice (Table 1) . Since it is known that heterozygous p53 þ /À mutant mice develop a variety of sarcomas including RMS, hemangiosarcoma and leiomyosarcoma (Harvey et al., 1993; Jacks et al., 1994) , we first excluded the latter two tumor types by staining with hematoxylin and eosin (H&E) and relevant markers, namely CD31 and smooth muscle actin (SMA) (Coindre, 2003) . As shown in Table 1 , all tumors examined were negative for these two markers. Next, we stained for desmin, a widely used marker for RMS (Coindre, 2003) , and found strong expression in all tumors examined, with desminpositive cells more prevalent in p53-dependent RMS. In addition, we stained for the antiapoptotic protein Bcl-2, which has recently been shown to be strongly expressed in 36% of human RMS, as well as in all cases of murine Ptch1-associated RMS (Boman et al., 1997; Kappler et al., 2003) . We found high levels of Bcl-2 protein in RMS from both Ptch1 neo67/ þ and p53 þ /À mice. Taken together these data identify the tumors under investigation as RMS that express the RMS-specific marker desmin and in addition Bcl-2 at similar levels.
Next, we examined biological parameters of the RMS from both genotypes. Proliferative activity was evaluated using the proliferation marker Ki-67 and histological analysis performed on H&E-stained tumor sections. A low density of Ki-67-positive proliferating tumor cells was seen in four out of five Ptch1-dependent RMS ( Figure 3c , Table 1 ). This was associated with a higher degree of histological differentiation, as indicated by tumor cells with a broad cytoplasm and focal striation (Figure 3a) , and with positive staining for desmin (Table 1 ). In contrast, p53-dependent RMS generally displayed a much more aggressive growth, with a high density of Ki-67 positive tumor cells, being present in four out of five RMS (Figure 3d ), which correlated with poor histological differentiation characterized by small spindle-shaped desmin-positive tumor cells (Table 1) , absence of further cytoplasmic differentiation and a high percentage of mitotic figures (Figure 3b ). One RMS of p53 þ /À origin (No. 728) displayed well-differentiated tumor cells with a very low number of Ki-67-positive tumor cells, thus resembling the Ptch1-associated tumor phenotype (Table 1 ). These results demonstrate that in general the Ptch1-dependent RMS show a less aggressive growth and are histologically more differentiated than p53-dependent RMS.
p53 signaling is preserved in RMS of Ptch1 neo67/ þ mutants Mutations in the p53 gene have been detected in nearly 50% of all cases of human RMS (Mulligan et al., 1990; Stratton et al., 1990; Felix et al., 1992) . In addition, it has been proposed that loss of p53 also plays a crucial role in the genesis of MB in Ptch1 þ /À mice (Wetmore et al., 2001) . We therefore investigated whether p53 signaling was disturbed in RMS of Ptch1 neo67/ þ mice. The analysis of p53 cDNA revealed no mutations in the coding region of p53 in any of the five tumors examined (data not shown). As it is generally assumed that mutations in the p53 gene are frequently associated with an increase in stability of the p53 protein in human tumors (May and May, 1999) , we investigated p53 protein levels by means of immunohistochemistry of formalin-fixed, paraffin-embedded tissue sections of five RMS of heterozygous Ptch1 neo67/ þ mice. Immunostaining using a monoclonal antibody against p53 revealed no accumulation of p53 protein in any of the tumor cases examined (data not shown).
To assess the status of the p53 signaling pathway in RMS of Ptch1 mutants, we investigated the expression of two downstream targets of p53 (p21 cip1/waf1 and Bax) and of p53 itself. Using quantitative RT-PCR we observed elevated levels of p53 transcripts in all RMS analysed ( Figure 4a ). Furthermore, we detected highly elevated transcript levels of p21 cip1/waf1 ( Figure 4b ) and Bax ( Figure 4c ). These results indicate that p53 signaling is activated in tumors of Ptch1 neo67/ þ mice, and suggested a wild-type function of p53 in tumor tissue. Moreover, our findings clearly demonstrate that RMS formation in heterozygous Ptch1 neo67/ þ mice is not dependent on mutation of p53. , 2002) . In order to determine whether the Hedgehog/Patched signaling pathway was also affected in RMS of p53 þ /À mutants, we performed semiquantitative RT-PCR of Gli1 and Ptch1. As shown in Figure 5 , the expression of both genes was elevated in the tumor tissues compared to the corresponding normal skeletal muscle (SM). As expected, the expression levels of both genes were significantly higher in the RMS tumors derived from Ptch1 neo67/ þ mice ( Figure 5 ).
Moderate activation of
Rhabdomyosarcomagenesis in heterozygous p53
þ /À mice does not involve loss of the wild-type p53 allele Both retention (Venkatachalam et al., 1998) and loss of the wild-type allele (Jacks et al., 1994) has previously been described in tumors arising in p53 þ /À mice. Therefore, we checked whether loss of both p53 alleles is necessary for tumor formation in p53 þ /À mice and whether the remaining wild-type p53 allele was deleted in RMS tissue derived from these mice. Using the reverse primer RT-p53 in conjunction with the primer p53-2 localized in exon 4 of p53 (deleted in the targeted p53 allele), a band of the appropriate size was detected in all tumors by semiquantitative RT-PCR (supplementary Figure A) . The remaining wild-type allele was sequenced in four RMS of heterozygous p53 þ /À mice. No mutations were detected in any of the samples examined (data not shown). These results demonstrate Hedgehog/Patched signaling in Ptch1-and p53-dependent RMS. Gli1 and Ptch1 expression was analysed in SM and RMS of p53 þ /À and Ptch1 neo67/ þ mice using semiquantitative RT-PCR, respectively. Gapd expression was monitored to control for the amount of sample RNA Patched-and p53-dependent rhabdomyosarcoma R Kappler et al that the wild-type p53 allele was retained in tumor tissue.
Expression profiling distinguishes between Ptch1-and p53-dependend RMS To determine if the specific gene defects lead to particular molecular changes during rhabdomyosarcomagenesis, we profiled gene expression of RMS of each genotype using SM tissue and C2C12 myoblasts as nonneoplastic controls. To this end, Cy5-labeled cDNA probes prepared from each test RNA sample and Cy3-labeled reference cDNA probes prepared from a pool of RNAs isolated from eight different mouse tissues were co-hybridized to Agilent's mouse cDNA microarrays containing 8400 mouse genes, including B3700 characterized genes from the Mouse UniGene database and B4700 nonannotated EST clones. The fluorescence ratio was quantified for each gene and reflected the relative abundance of the gene in each test RNA sample compared with the reference RNA pool. The use of a common reference probe allowed us to treat these fluorescent ratios as measurements of the relative expression level of each gene across all 13 samples. Data restriction left 2852 genes (B34%) in the data set, which is available as a supplementary Table A . A hierarchical clustering algorithm was used to group tumor samples on the basis of similarities in their expression of these genes. As depicted in Figure 6 , RMS and SM of heterozygous Ptch1 neo67/ þ mice and the C2C12 cells clustered into one group, whereas RMS of heterozygous p53 þ /À mice were clustered as a second group. Furthermore, the same algorithm was used to cluster genes on the basis of similarity in the pattern with which their expression varied over all samples. The data are shown in a matrix format (Figure 6 ), with each row representing all the hybridization results for a single cDNA element of the array, and each column representing the measured expression levels of all genes in an individual sample. One of the clearest distinctions in the gene expression patterns of the two RMS subtypes are the subset of genes that are known as myogenic markers ( Figure 6 , middle panel) including myosin heavy polypeptide 1, tropomyosin 2 beta, troponin I and troponin T3. This group of genes was more highly expressed in Ptch1-associated RMS than in p53-associated RMS. The same set of genes was strongly expressed in SM tissue, but not in C2C12 cells. Another interesting cluster of genes sharing differentially expression between the two RMS subtypes contained genes associated with Hedgehog/ Patched signaling ( Figure 6 , upper panel), namely Igf2 (Hahn et al., 2000) , forkhead box gene Foxf1 (Kappler et al., 2003) , the growth arrest and DNA-damageinducible gene Gadd45a (Kappler et al., 2004) , and caveolin 3 (Cav3) (Karpen et al., 2001) . These genes generally exhibited higher transcript levels in Ptch1-dependend RMS rather than in p53-dependend RMS or SM tissue and C2C12 cells. A cluster displaying genes with higher transcript levels in p53-dependend RMS contained the cell cycle-associated genes cyclin B1 (Ccnb1), activator of S phase kinase and the proliferation marker Ki-67 ( Figure 6 , lower panel). These genes were also strongly expressed in C2C12 cells, but displayed only low levels in SM tissue.
By compiling sets of genes that vary significantly in their mean relative expression between the two RMS subtypes (Tables 2 and 3) , we detected several genes previously associated with rhabdomyosarcomagenesis or myogenic differentiation, namely Fos (Fleischmann et al., 2003) , myogenic differentiation 1 (MyoD1) (Kablar et al., 2003) , Junb (Chalaux et al., 1998) , follistatin (Amthor et al., 2002; Armand et al., 2003) , heparin binding epidermal growth factor-like growth factor (Chen et al., 1995) , matrix metalloproteinase 9 (Kherif et al., 1999) and p21 cip1/waf1 (see Figure 4b ). These genes generally displayed higher transcript levels in Ptch1-dependend RMS than in p53-dependend RMS (Table 2) . On the other hand, we detected several genes like catenin beta, cadherin 2, cyclin-dependent kinase 4 (Cdk4a), biglycan and platelet-derived growth factor C that were expressed at significant higher levels in p53-dependend RMS than in Ptch1-dependend RMS (Table 3) .
A number of the candidate genes identified by microarray analysis were validated by semiquantitative RT-PCR. As shown in Figure 7 , the expression of MyoD1, Igf2, Foxf1, Cav3 and Gadd45a was increased, whereas the expression of Cdk4 and Ccnb1 was decreased in Ptch1-dependend RMS compared to p53-dependend RMS. Altogether, microarray analysis revealed distinct gene expression signatures in Ptch1-and p53-derived RMS.
Discussion
The goal of this study was to gain insight into the molecular events that drive p53-or Ptch1-dependent rhabdomyosarcomagenesis, and to establish their characteristic molecular signatures. To this end, we compared biological, histological and molecular profiles of RMS arising in mice bearing targeted genetic defects in p53 and Ptch1. To confirm the respective genetic defects, we firstly have verified the allelic status of each tumor suppressor gene in the respective tumors. We also ruled out severe alterations of p53 signaling in Ptch1-associated and of Hedgehog/Patched signaling in p53-associated tumors. However, some feature are shared by both tumor subtypes, notably expression of markers for RMS such as desmin and Bcl-2 (Boman et al., 1997; Merlino and Helman, 1999; Kappler et al., 2003) , and the pattern of distribution of tumors to the trunk and extremities. The subtypes differed from each other in several points. RMS of Ptch1 heterozygous mice were histologically well differentiated with a low proliferation index, whereas p53-dependent RMS generally display a more aggressive and less differentiated small blue round cell phenotype. Moreover, the two RMS subtypes differ in the time of onset and incidence.
Most importantly, the two murine RMS subtypes differed dramatically in their gene expression profiles. The specific transcriptional signature of each tumor can Patched-and p53-dependent rhabdomyosarcoma R Kappler et al be summarized as follows: (i) RMS of heterozygous Ptch1 neo67/ þ mice show higher transcript levels of known myogenic differentiation markers; (ii) p53-dependent RMS exhibit stronger expression of cell cycle-associated genes; and (iii) transcripts of genes described to play a role in Hedgehog/Patched signaling are more abundant in RMS of heterozygous Ptch1 neo67/ þ mice. These findings are consistent with previous observations in human and murine RMS.
First, using cDNA microarray analysis on human RMS cell lines with different differentiation properties, it has been described that almost half of the genes with higher expression in more differentiated RMS cells were markers of terminal myogenic differentiation, such as differentiation, resulting in the high expression of late markers of differentiation. This conclusion is furthermore strengthened by our findings that Ptch1-dependent RMS and normally differentiated SM tissue display similar levels of muscle-specific gene expression, in contrast to the situation found in proliferating C2C12 myoblasts, which represent multipotent mesenchymal (Wada et al., 2002) . Second, using again cDNA microarray analysis it has been demonstrated that differentiating C2C12 myoblasts, a well-established in vitro model for muscle differentiation, show expression patterns consistent with cell cycle withdrawal (Shen et al., 2003) . Compared with proliferating cells, differentiating myotubes exhibited a strong decrease in cell cycle-associated genes such as Ccnb1 and Cdk4. Since we found high expression levels of these genes in p53-dependent RMS, it is highly probable that this more aggressive subtype arises through the maintenance of proliferative activity of mesenchymal myogenic progenitor cells, and through a block of these cells very early in terminal muscle differentiation, as evidenced by the low expression of appropriate markers. This assumption is strengthened by our finding that both SM, which is a G0 phase tissue, as well as the well-differentiated Ptch1-dependent subtype of RMS, lack expression of relevant cell cycleassociated genes.
Third, the relative abundance of genes such as Igf2, Foxf1, Gadd45a and Cav3 in RMS of heterozygous Ptch1 neo67/ þ mice in comparison to tumors of p53
mice is consistent with their involvement in Hedgehog/ Patched signaling (Hahn et al., 2000; Karpen et al., 2001; Kappler et al., 2003 Kappler et al., , 2004 . It has previously been described that Igf2 is highly expressed in RMS of heterozygous Ptch1 neo67/ þ mice, and that it is indispensable for tumor formation (Hahn et al., 2000) . Furthermore, LOH or LOI at the 11q15 locus, a region harboring the human IGF2 gene, is characteristic for human ERMS, and may contribute to the overexpression of IGF2 observed in these tumors (Zhan et al., 1994) . Thus, IGF2 expression may provide a good marker for a less aggressive and prognostically favorable subtype of RMS. Caveolins interact with signaling molecules in a number of key pathways, including endothelial nitric oxide synthase, src family tyrosine kinases, ras, protein kinase A (Couet et al., 2001) and Ptch1 (Karpen et al., 2001) . Whereas Cav1 has already been widely implicated as a tumor suppressor gene, data on Cav3 and its role in carcinogenesis are limited. Significantly, Cav3 expression is confined to muscle cells, and it has been suggested that Cav3 has a specialized role associated with the differentiated state in this cell type (Doyle et al., 2003) . Thus, the higher expression of Cav3 in RMS of heterozygous Ptch1 neo67/ þ mice is consistent with the higher differentiation properties of this tumor subtype, rather than an indication for regulation of this gene by an activated Hedgehog/ Patched pathway.
Another gene that was upregulated in Ptch1-associated RMS is p21 cip1/waf1
. In humans, p21 cip1/waf1 expression has been demonstrated to be higher in ERMS compared with ARMS (Moretti et al., 2002) . It is known that expression of this cell cycle inhibitor is under the control of multiple transcriptional factors, including p53 and MyoD1. In our study the function of the p53 signaling pathway may even be preserved and seems to be activated in Ptch1-associated RMS, probably as a result of the cellular regulatory network to protect the organism by stimulating growth arrest and apoptosis. However, as MyoD1 expression was also increased in these tumors (see Table 2 ) we cannot ascertain whether the elevated levels of p21 cip1/waf1 are the result of p53 or MyoD1 expression.
An assignment of the Ptch1-and p53-dependent subtypes to one specific human form of RMS is clearly not possible at that stage, since the gene expression profiles of the latter have yet to be investigated. However, the differentiation properties, histology, expression of terminal myogenic differentiation markers, and expression of Igf2 and p21 cip1/waf1 in RMS of Ptch1 neo67/ þ mice mostly associated with human ERMS. The earlier occurrence of Ptch1-dependent RMS is consistent with such a suggestion (Wexler and Helman, 1997) . The less differentiated phenotype with small round densely packed cells and the high expression levels of cell cycle-associated genes of the p53-dependent RMS resembles human ARMS, which occur in an older age group (Merlino and Helman, 1999) . If the gene profile is found and confirmed in human RMS, these differences may have significance for the treatment of this cancer. Given that (a) p53 is required for the induction of apoptotic cell death by ionizing radiation and some types of chemotherapeutic drugs (May and May, 1999); (b) Hedgehog/Patched signaling can be specifically blocked by either the alkaloid cyclopamine Figure 7 Verification of microarray findings. To confirm the expression profile for genes obtained from the cDNA microarray analysis, the expression level of selected genes from Tables 2 and 3 was examined in RMS of Ptch1 neo67/ þ and p53 þ /À heterozygous mice by means of semiquantitative RT-PCR. Gapd expression was monitored to control for the amount of sample RNA (Taipale et al., 2000) or inhibitory small molecules (Williams et al., 2003) ; (c) Igf2 accumulation can be selectively targeted by a methylated oligonucleotide inhibition strategy (Yao et al., 2003) ; and (d) butyrate can be used to induce an increase of cell cycle inhibitors like p21 cip1/waf1 and thereby induce growth inhibition in RMS cells (Moretti et al., 2002) , classification of RMS on the basis of expression information may serve as a step toward defining a new molecular taxonomy of this solid childhood cancer, resulting in the development of gene mutation-and expression-specific therapies. The study presented here is a first step towards such a classification.
Materials and methods
Mouse breedings and crosses
Animal experiments were performed according to all necessary legal requirements. Mice heterozygous for Ptch1 neo67/ þ and p53 þ /À on a mixed C57BL/6 Â CD-1 background were genotyped according to published PCR protocols (Jacks et al., 1994; Hahn et al., 1998) , except that the primer W3 0 used for amplification of both the wild-type and the mutant p53 allele was 5 0 -TGGTATACTCAGAGCCGGCCT-3 0 . Mice were monitored for tumor formation weekly.
Tissue specimens
Tumors were surgically removed from muscle tissue and cut into two parts. Specimens to be used for isolation of total RNA (see below) were immediately frozen in liquid nitrogen. The remainder was formalin-fixed and embedded in paraffin for immunohistochemical analysis. The identity of the tumors was established on H&E stained sections by a trained pathologist. Only RMS tissues containing >95% tumor cells were used in this study.
Immunohistochemistry
For immunohistochemical analyses 3-mm-thick paraffin sections were mounted on organo-silane coated slides. After deparaffination and rehydration the endogenous peroxidase activity was quenched with 3% hydrogen peroxide. For antigen retrieval the tissue sections were either microwaved in citrate buffer at 700 W for 15 min (for antibodies 1 and 4) or digested with protease XXIV for 20 min at 371C (for antibodies 2, 3 and 5). Primary antibodies were diluted in Tris-buffered saline (pH 7.5) containing 5% bovine serum albumin. The antibody panel included: (1) monoclonal mouse anti-Ki-67 (Novacastra Laboratories, Newcastle upon Tyne, UK) diluted 1 : 50; (2) monoclonal mouse anti-Desmin (Sigma, Munich, Germany) diluted 1 : 50; (3) monoclonal mouse antihuman CD31 (Dianova, Hamburg, Germany) diluted 1 : 50; (4) polyclonal rabbit anti-human Bcl-2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) diluted 1 : 40; and (5) monoclonal mouse anti-p53 (Santa Cruz Biotechnology) diluted 1 : 100. After incubation of the sections with the primary antibodies and subsequent incubation for 30 min with Envisiont-Peroxidase (DakoCytomation, Hamburg, Germany), signals were detected with diaminobenzidine and counterstained with hematoxylin. Smooth muscle actin was labeled using a monoclonal mouse anti-SMA antibody directly conjugated with alkaline phosphate (Sigma) diluted 1 : 50 and nitro tetrazolium blue/5-bromo-4-chloro-indolyl phosphate as chromogen.
Isolation of RNA
Total RNA was extracted from RMS and normal SM tissue of heterozygous
þ /À mice of the F1 generation, C2C12 myoblasts (American Type Culture Collection, Manassas, VA, USA) grown for 72 h in growth medium (DMEM supplemented with 10% FCS), and from various other tissues (kidney, liver, spleen, muscle, brain, lung, testis, heart) of wild-type mice using TRIZOL reagent (Invitrogen, Carlsbad, CA, USA). Total RNA of the latter tissues was pooled and used as a universal reference RNA in cDNA microarray experiments. For these experiments total RNA was further purified using RNeasy columns (Qiagen, Hilden, Germany). The quality of RNA was checked by the 2100 bioanalyser (Agilent Technologies, Palo Alto, CA, USA) using the RNA 6000 Nano LabChip Kit (Agilent Technologies).
cDNA microarray analysis
The gene expression profiles of RMS of heterozygous Ptch1 neo67/ þ and p53 þ /À mice, SM of a heterozygous Ptch1 neo67/ þ mouse as well as C2C12 cells were determined using mouse cDNA microarray kits purchased from Agilent Technologies. Briefly, equal amounts (20 mg) of total RNA from universal reference and test samples were each reversetranscribed in a total volume of 50 ml with 2 mg oligo(dT) [12] [13] [14] [15] [16] [17] [18] primers and 400 U SuperScriptII reverse transcriptase (Invitrogen) in the presence of 0.025 mM Cy3-or Cy5-dUTP (NEN Life Science Products, Boston, MA, USA). After 2 h incubation at 421C, the reaction was stopped by heating for 10 min at 701C. Template RNA was degraded by incubating with RNase H (Roche Diagnostics, Mannheim, Germany) for 30 min at room temperature. Unincorporated nucleotides were removed from labeled cDNA using QIAquick PCR purification columns (Qiagen). The differentially labeled cDNAs from the reference and test samples were combined, 2.5 mg mouse C 0 t1 DNA (Invitrogen) was added, and the mix was dried to completion. The probe was resuspended in 25 ml deposition hybridization buffer (Agilent Technologies), denatured for 5 min at 951C and hybridized overnight at 651C to mouse cDNA microarrays under a lifterslip (Erie Scientific Company, Portsmouth, NH, USA) in a hybridization chamber (Scienion, Berlin, Germany). After hybridization, slides were washed 3 Â 5 min in 0.5 Â SSC/0.01% SDS and 1 Â 5 min in 0.06 Â SSC with moderate agitation. Slides were quickly transferred into swinging buckets in a benchtop centrifuge and dried for 2 min at 400 g. The fluorescent signal of hybridized molecules was detected for Cy3 (universal reference) and Cy5 (test sample) using Agilent's dual-laser Microarray Scanner and data acquisition was performed with the G2566AA Feature Extraction software (Agilent Technologies). This software was furthermore used to subtract the local background from the features and to normalize the data by utilizing a method that is based on rank-ordered consistency. The resulting data were used to calculate the ratio of gene expression in test sample versus the universal reference. These relative gene expression values were used to calculate the average relative gene expression of six Ptch1 and five p53 tumors, respectively. Fold changes were determined (average of Ptch1-mutant tumor samples/average of p53-mutant tumor samples) and the data set was restricted by using at least a two-fold difference as a filter cutoff. The selected group of genes was examined by hierarchical cluster analysis to find subgroups of genes based on similar expression patterns. Preceding the clustering analysis all ratio values were log-transformed (base 2) and filtered to reach 70% presence of cases. We applied hierarchical clustering to both axes, using the weighted pair-group algorithm with a centroid average as implemented in the program CLUSTER (http://microarrays.org/software.html). The results were visualized by using the TREEVIEW matrix (http://microarrays.org/software.html). We selected candidate genes by requiring their relative gene expression levels to yield Po0.05 for the standard Student's t-test in Ptch1-and p53-mutant RMS, as well as giving at least a two-fold increase/ decrease in the gene expression ratio.
Reverse transcription-PCR
Reverse transcription of total RNA from RMS of heterozygous Ptch1 neo67/ þ and p53 þ /À mice was performed using random hexamers and SuperScriptII reverse transcriptase (Invitrogen).
Semiquantitative PCR amplifications of the murine genes MyoD1, Igf2, Foxf1, Cav3, Gadd45a, Ccnb1, Cdk4, Gli1, Ptch1 and glyceraldehyde-3-phosphate dehydrogenase (Gapd) were carried out with 50 ng of cDNA using the forward (F) and reverse (R) primers as follows: MyoD1-F 5 0 -AAAGTGAAT GAGGCCTTCGAGAC-3 0 and MyoD1-R 5 0 -AAGCACCT GATAAATCGCATTGGG-3 0 ; Igf2-F 5 0 -GACGACTTCCC CAGATACCCCGTG-3 0 and Igf2-R 5 0 -TCACTGATGGTT GCTGGACATCTC-3 0 ; Foxf1-F 5 0 -CTCATCGTCATGGC TATCCAGA-3 0 and Foxf1-R 5 0 -GAGGCTGTTGCTTGAT GTAGGA-3 0 ; Cav3-F 5 0 -ATGATGACCGAAGAGCACAC GGAT-3 0 and Cav3-R 5 0 -TTAGCCTTCCCTTCGCAGCAC CAC-3 0 ; Gadd45a-F 5 0 -TGCAGAGCAGAAGACCGAAAG GAT-3 0 and Gadd45a-R 5 0 -TTAAGGCAGGATCCTTCCA TTGTGA-3 0 ; Ccnb1-F 5 0 -TGACAGTTACTGCTGCTTCCA AG-3 0 and Ccnb1-R 5 0 -CTGTATTAGCCAGTCAATGAG GAT-3 0 ; Cdk4-F 5 0 -GGAAACTCTGAAGCCGACCAGTT G-3 0 and Cdk4-R 5 0 -ACTCTGCGTCGCTTTCCTCCTTG-3 0 ; Gli1-F 5 0 -GGCTTTCATCAACTCTCGCTGTAC-3 0 and Gli1-R 5 0 -AGCTTGCACACGTATGGCTTCTC-3 0 ; Ptch1-F 5 0 -TTC TGCTGCCTGTCCTCTTATC-3 0 and Ptch1-R 5 0 -GCCAGAA TGCCCTTCAGTAGAA-3 0 ; Gapd-F 5 0 -ATCTTCTTGTGCA GTGCCAG-3 0 and Gapd-R 5 0 -ATGGCATGGACTGTGGTC AT-3 0 . PCR reactions were performed in a 20 ml final reaction mixture for 25-28 cycles consisting of 30 s denaturation at 951C, hybridization of primers for 30 s at 551C and extension for 1 min at 721C. The individual cycle number for each gene was defined by predetermining the linear range of the PCR. Amplification of Gapd was used as a reference standard to control for the amount of sample RNA.
Quantitative real-time PCR was carried out using an ABI PRISM 7700 sequence detector (Applied Biosystems, Foster City, CA, USA) as previously described (Calzada-Wack et al., , and Bax1, respectively. Amplification of Gapd as an endogenous control was performed to standardize the amount of sample RNA. The Gapd primers were 5 0 -TCCATGCCATCACTGCCA-3 0 and 5 0 -GATGCAGGGATGATGTTCTGG-3 0 , and the fluorogenic probe was 5 0 -CAGAAGACTGTGGATGGCCCCT C-3 0 . PCR amplifications were carried out with the TaqMan Universal PCR Master Mix (Applied Biosystems) using 50 ng of cDNA, 200 nM of probe, and 300 nM forward and reverse primers in a 30 ml final reaction mixture. After 2 min incubation at 501C, AmpliTaq Gold was activated by incubation for 10 min at 951C. Each of the 50 PCR cycles consisted of 15 s denaturation at 951C and hybridization/ extension of probe and primers for 1 min at 601C. All data shown are the average of at least two independent experiments.
Sequencing of murine p53
Murine p53 cDNA was prepared by reverse transcription of total RNA isolated from five RMS of Ptch1 neo67/ þ mice and from four RMS of p53 þ /À mice using RT-p53 primers (RTp53-F 5 0 -CTGGCTGTAGGTAGCGACTA-3 0 and RT-p53-R 5 0 -AACTTGGGCCAGGAACCACT-3 0 ) and SuperScriptII reverse transcriptase (Invitrogen). The entire coding sequence was screened for mutations by sequencing four overlapping fragments (primers were RT-p53-F; RT-p53-R; p53-2 5 0 -GCCAAGTCTGTTATGTGCACG-3 0 ; p53-3 5 0 -ATGTG TAATAGCTCCTGCATGGGG-3 0 ). Sequencing was performed using an ABI PRISM 377 DNA Sequencer (Applied Biosystems) and BLAST searches were carried out with the NCBI network service (http://www.ncbi.nlm.nih.gov/blast/ blast.cgi).
